Quantcast

Optical Biopsy Device Evaluates Flat Polyps During Colonoscopies

December 18, 2008

SAN DIEGO, Dec. 18 /PRNewswire-FirstCall/ — SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today commented on the recent media coverage of a Canadian study which shows the limitations of colonoscopies in detecting cancer. The study reports that the procedure may detect polyps and early cancerous tissue only 60 to 70 percent of the time. SpectraScience announced today that the significant rate of missed cancers during colonoscopies may be greatly improved by the use of the Company’s WavSTAT(R) Optical Biopsy System.

Tuesday’s article in the Journal, Annals of Internal Medicine found that traditional colonoscopy, while widely recommended, was much less accurate than anyone expected. Scientists at SpectraScience pointed out that using a safe low power laser to illuminate tissue in the colon, the WavSTAT system, when combined with a physician’s visual assessment can tell within seconds if the tissue is “normal” or “suspect” with 96% sensitivity.

SpectraScience CEO, Jim Hitchin, said that “The WavSTAT can provide physicians, which otherwise rely on the naked eye and experience, with a much more objective cancer screening tool that will increase their success rate, saving more lives and reducing healthcare expenses overall.”

Using the principle of Laser Induced Fluorescence (LIF), diseased or cancerous tissue fluoresces differently compared to normal healthy tissue. Diseased tissue has reduced fluorophors which when analyzed by a specialized detector can indicate with high sensitivity that the cells are becoming dysplastic, a precursor to cancer.

During colonoscopy, a small fiber optic probe is directed by the clinician to touch the suspicious tissue. Depressing a foot switch directs low powered, safe laser light into the tissue. The laser shuts off and the tissue fluorescence light is directed back up the same fiber optic probe to a specialized detector. The system’s computer analyses the detectors output and within seconds displays a RED or GREEN light on a screen. A GREEN light means the tissue is “normal” with 96% sensitivity. Where a flat polyp is suspect, multiple uses of the optical fiber and the RED light may assist the clinician in determining the margin of the “suspect” tissue and remove all of it in the same procedure.

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending on its WavSTAT(R) Optical Biopsy System and LUMA(R) Cervical Imaging Systems. These devices are used to assess tissue quickly to help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat (“Barrett’s esophagus”) is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods currently available.

    Contact:
    SpectraScience, Inc.
    Jim Hitchin, Chief Executive Officer
    (858) 847-0200 x201

    Hayden Communications
    Investor Relations
    Todd Pitcher
    (858)-518-1387

SOURCE SpectraScience, Inc.


Source: newswire



comments powered by Disqus